← Back to Search

3D translabial ultrasound for Pelvic Organ Prolapse

N/A
Waitlist Available
Research Sponsored by Western University, Canada
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 hour and 20 minutes (i.e. the estimated time for the ultrasound and manometry examination per participant).
Awards & highlights
No Placebo-Only Group

Summary

This is a feasibility study looking at the use of 3D ultrasound with vaginal manometry at various distension volumes to predict the best available pessary for successful fit.

Eligible Conditions
  • Pelvic Organ Prolapse

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 hour and 20 minutes (i.e. the estimated time for the ultrasound and manometry examination per participant).
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 hour and 20 minutes (i.e. the estimated time for the ultrasound and manometry examination per participant). for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Ultrasonography
Secondary study objectives
Survey

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: 3D translabial ultrasoundExperimental Treatment1 Intervention
3D translabial ultrasound with concurrent vaginal manometry

Find a Location

Who is running the clinical trial?

Western University, CanadaLead Sponsor
253 Previous Clinical Trials
58,551 Total Patients Enrolled
Cosm Medical CorporationUNKNOWN
~4 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top